Combination Regimens Take Center Stage in Frontline NSCLC @myesmo.bsky.social #ESMOAsia25 #lcsm #oncology www.onclive.com/view/combina...
0
0
0
0
Hashtag
#ESMOAsia25
Advertisement · 728 × 90
New prospective data from #ESMOAsia25 show that in MRI-positive #ProstateCancer, TB+iSB is non-inferior to standard TB+SB, potentially streamlining diagnosis and reducing unnecessary biopsy cores.
#ESMODailyReporter 📌 https://ow.ly/5hUa50XTkno
1
0
0
0
KANDLELIT-001:As presented at #ESMOAsia25, the next-generation KRAS G12C inhibitor MK-1084 continues to show manageable safety and encouraging antitumour activity in advanced #CRC, as monotherapy and in combination regimens.
#ESMODailyReporter 📌 https://ow.ly/hkAI50XTkiQ
0
0
0
0
In the #ESMODailyReporter, Umberto Malapelle explains how concomitant analysis of DNA and RNA can advance cancer characterisation and guide clinical decision making, highlighting data presented at #ESMOAsia25
📌 https://ow.ly/bGI350XM8f6
#PrecisionOncology
4
2
0
0
Friends of Max - Viji Venkatesh Represents at ESMO Asia 2025 Patient Engagement Summit
oncodaily.com/voices/viji-...
#ESMOAsia25 #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
3
0
0
0
🌍 Uniting the Asia-Pacific oncology community: 4,550+ participants, 170+ speakers, 71 sessions, 70+ countries & 940+ abstracts.
🙌 ESMO Asia 2025 sets a new record in advancing cancer care in Asia! #ESMOAsia25 #esmomeetings
🔗 https://ow.ly/aiwM50XGitY
1
0
0
0
🙌 To everyone who powered ESMO Asia 2025—thank you! From pioneering science to global collaboration, your contributions shaped an inspiring congress.
📅 See you next year in Singapore, 4–6 Dec 2026! #esmomeetings #ESMOAsia25
🔗 buff.ly/J1q4Zzv
2
1
0
0
20 Posts Not to Miss from ESMO Asia 2025
@myesmo.bsky.social
oncodaily.com/not-to-miss/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMOAsia25
2
0
0
0
The IKCC team is fully mobilised for #ESMOAsia25 in Singapore. Dr Munisamy Murallitharan shared the results from the IKCC global patient survey on “knowledge gaps and disparities in kidney cancer across Asia”, during a session chaired by Ravindran Kanesvaran. (1/3)
0
0
1
0
#ESMOAsia25: Studies in cancer of unknown primary (#CUP) highlight the need to perform routine comprehensive #GenomicProfiling and then provide access to the appropriate #TargetedTherapy. Find out more in the #ESMODailyReporter ➡️https://ow.ly/sK6H50XF5t7
3
2
0
0
#ESMOAsia25: #ClinicalTrials investigated antibody–drug conjugates (#ADCs) with payloads other than topoisomerase I inhibitors and targets beyond HER2 in attempts to minimise cross-resistance. Read more in the #ESMODailyReporter ➡️https://ow.ly/Eb7l50XF5sN
Paolo Tarantino, MD
3
0
0
0
Foundation Medicine Booth Talks at ESMO Asia Congress 2025 - Sunday schedule
Join us at booth B111, hall 4 at #ESMOAsia25 for our final booth talks, including sessions around Foundation Medicine’s tissue-based RNA sequencing test, our clonal hematopoiesis algorithm and use cases around AI and precision medicine. Find out more: spkl.io/63320Agvl6
0
0
0
0
Discussing Potentials and Implications of AI-Driven Biomarkers in Oncology Clinical Care at ESMO Asia 2025 - Herbert Loong
@herbloongmd.bsky.social
@myesmo.bsky.social
oncodaily.com/voices/herbe...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMOAsia25 #ESMOAsia2025
3
0
0
0
Inside ESMO Asia 2025 with Angela Lamarca
@myesmo.bsky.social
oncodaily.com/voices/esmo-...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMOAsia #ESMOAsia25 #ESMOAsia2025
2
0
0
0
Inside ESMO Asia 2025 with David Planchard
@myesmo.bsky.social
oncodaily.com/voices/esmo-...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMOAsia #ESMOAsia25 #ESMOAsia2025
2
0
0
0
Inside ESMO Asia 2025 with Deborah Mukherji
@dmukherji.bsky.social
@myesmo.bsky.social
oncodaily.com/voices/esmo-...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMOAsia #ESMOAsia25 #ESMOAsia2025
2
0
0
0
#ESMOAsia25: Impressive results from the Chinese LUMINET-1 phase III trial confirm and extend previous findings with 177Lu-DOTATATE in patients with gastroenteropancreatic neuroendocrine tumours (#GEP-NETs).
Read more in the #ESMODailyReporter ➡️https://ow.ly/mUuE50XEwSo
2
1
0
0
Josephine Contreras-Tolentino discusses why acknowledging population diversity matters. As shown at #ESMOAsia25, ethnicity differences can impact on presentation and tolerability, which can influence treatment selection.
➡️Read more: https://ow.ly/161g50XEwRu
#ESMODailyReporter
2
1
0
0
Foundation Medicine Booth Talks at ESMO Asia Congress 2025 - Saturday schedule
Our #BoothTalks series are underway at #ESMOAsia25! Learn more about Saturday’s sessions below. Click here for more information: spkl.io/63320AgmGr
0
0
0
0
#ESMOAsia25: Encouraging phase II findings were presented with the p53 reactivator, rezatapopt, in patients with heavily pre-treated solid tumours expressing the TP53 Y220C mutation.
📌Read more: https://ow.ly/htXy50XCCKL
#ESMODailyReporter
5
1
0
1
ESMO is excited to announce the #ESMOMeritAward recipients, selected by the Congress Scientific Committee for the exceptional scientific merit of their abstracts. #ESMOAsia25
📌 https://ow.ly/tko150XCK64
2
1
0
0
#ESMOAsia25: The CLDN18.2-targeting antibody–drug conjugate (#ADC), JS107 in combination, achieved an impressive response rate in the first-line treatment of CLDN18.2-high #GastricCancer in a phase I #ClinicalTrial.
📌 Read more: https://ow.ly/MIw750XCBfZ
#ESMODailyReporter
2
1
0
0
🙌Today, we witnessed the power of togetherness at #ESMOAsia25. Crowded rooms, meaningful discussions, and groundbreaking research, all united by one mission: improving patient outcomes in Asia. #esmomeetings
👉 Together, we shape the future of oncology: buff.ly/qHVAi4F
4
2
0
0
In the #ESMODailyReporter, Eileen Yi Ling Poon discusses addressing the medical and psychosocial needs of adolescents and young adults (#AYA) w/ cancer, providing individualised treatment, targeted emotional support and age-appropriate information: https://ow.ly/O94S50XCBee
#ESMOAsia25
3
4
0
0
📣 Welcome to ESMO Asia 2025!
Together we bring dedication, expertise and shared purpose to one of the most important oncology meetings in the Asia-Pacific region.
Let’s move forward as one. #ESMOAsia25 #esmomeetings
🔗 buff.ly/z5gybDc
1
1
0
0
Foundation Medicine Booth Talks at ESMO Asia Congress 2025 - Friday Schedule
Attending #ESMOAsia25? Join us tomorrow as we kick off our “Booth Talks” – booth B111, hall 4. Learn about Friday's programming below. Want to connect with our team? Find the full Booth Talks schedule and more information here: spkl.io/63323AgkSS
0
0
0
0
We are looking forward to #ESMOAsia25 this week in Singapore. Eric Jonasch, Anne Wilson and Olivier Exertier will represent IKCC at this event with oncology experts from across the Asia-Pacific region.
2
0
0
0
Traveling to Singapore for #ESMOAsia25. Looking forward to meeting with friends and colleagues and discussing new therapeutic options for patients with #GI cancers #HCC #CCA #BTC @myesmo.bsky.social
4
0
0
0
ESMO Asia 2025 - Industry Satellite Symposium
Join us for an afternoon with international experts exploring recent advancements in complex biomarkers and the transformative impact of comprehensive genomic profiling (CGP) testing on patient outcomes, supported by real-world cases.
The schedule for the talks as outlined, including sessions on comprehensive genomic profiling, emerging complex biomarkers and RNA profiling.
Symposium will close on a session on liqui biopsy and a wrap up highlights sessions.
Join us for an industry satellite symposium at #ESMOAsia25 “From Insights to Outcomes: How Comprehensive Genomic Profiling Redefines Cancer Care.” Learn more below!
Connect with our team at this year’s meeting: spkl.io/63329AeIrU
0
0
0
0
Visit Foundation Medicine at Booth 4111, Hall 4 at ESMO Asia 2025
At #ESMOAsia25, Foundation Medicine is excited to join industry peers from across the Asia-Pacific region to discuss the latest research & innovations happening in oncology. Visit Foundation Medicine at booth B111, hall 4 to meet with our team. Learn more: spkl.io/63327AeniJ
1
0
0
0